<DOC>
	<DOCNO>NCT02266706</DOCNO>
	<brief_summary>The purpose study ass pharmacokinetics , safety , tolerability single intravenous dose ceftolozane/tazobactam pediatric participant . Ceftolozane/tazobactam novel antibacterial consist ceftolozane , unique antipseudomonal cephalosporin , tazobactam , well-established β-lactamase inhibitor . This first study investigate use ceftolozane/tazobactam pediatric participant .</brief_summary>
	<brief_title>Pharmacokinetic Safety Study Ceftolozane/Tazobactam Pediatric Participants Receiving Antibiotic Therapy Proven Suspected Gram-negative Infection Peri-operative Prophylaxis ( MK-7625A-010 )</brief_title>
	<detailed_description>Screening assessment occur within 48 hour study drug administration ( Day 1 ) . Baseline assessment perform follow eligibility verification base screening assessment . Participants monitor safety 24 hour post study drug infusion . The site contact participant and/or parent ( appropriate legal representative ) via telephone Study Day 8 ( ± 2 day ) assessment adverse event concomitant medication procedure . In age cohort , interim analysis PK safety data conduct 3 participant receive initially propose dose . The interim analysis determine whether initial dose appropriate base pre-defined criterion . If data interim analysis demonstrate initially propose dose meet criterion , enrollment continue dose administer 3 additional participant . However , interim analysis demonstrate new optimize adjust dose require , new adjust dose administer 3 new participant age range . In subsequent cohort , initial dose also subject change base upon result interim analysis previous cohort .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Bacterial Infections</mesh_term>
	<mesh_term>Gram-Negative Bacterial Infections</mesh_term>
	<mesh_term>Anti-Bacterial Agents</mesh_term>
	<mesh_term>Tazobactam</mesh_term>
	<mesh_term>Penicillanic Acid</mesh_term>
	<mesh_term>Cephalosporins</mesh_term>
	<mesh_term>Ceftolozane , tazobactam drug combination</mesh_term>
	<criteria>Key 1 . Males nonpregnant female birth &lt; 18 year age 2 . Receiving standard care antibiotic therapy suspect diagnosed Gramnegative infection perioperative prophylaxis 3 . Groups 14 : Calculated creatinine clearance rate ( CLCR ) ≥ 80 ml/min/1.73m2 baseline 4 . Group 5 : CLCR ≥ 50 ml/min/1.73m2 baseline 5 . Group 6 : CLCR ≥ 20 ml/min/1.73m2 baseline Key 1 . Known allergy/hypersensitivity βlactam antibacterial 2 . History clinically significant renal , hepatic , hemodynamic instability 3 . Planned use cardiopulmonary bypass dialysis 4 . Planned blood transfusion within 24 hour study drug administration 5 . Clinically significant abnormal laboratory test result related underlying infection 6 . Receipt piperacillin/tazobactam within 24 hour study drug administration 7 . Likely risk hemodynamic disturbance follow collection require PK blood sample</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>